OOIR: Observatory of International Research

Papers

(The TQCC of JACC-Heart Failure is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Clinical Implications of the P.V142I TTR Variant	269
Pulmonary Artery Catheter Timing and Outcomes for Patients With Cardiogenic Shock	214
Reply	171
Reply	134
Geographic Variation in the Quality of Heart Failure Care Among U.S. Veterans	113
Examination of Initiation Patterns for Sacubitril/Valsartan Among Older Adults With HFrEF in the United States	95
CHIEF Effects of Sodium Glucose Co-Transporter Inhibitors on Health-Related Quality of Life in Heart Failure	91
Long-Term Effects of Sotatercept on Right Ventricular Function	87
Developing a System for Best Performance for Cardiac Transplantation	78
Reply	73
Reply	72
Editorial Board	72
Correction	69
Curing Ourselves of Toxic Positivity for Hospital-at-Home	68
Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction	67
Full issue PDF	66
Myeloperoxidase in Heart Failure With Preserved Ejection Fraction	65
Clinical Inertia Disturbs the Harmonious Treatment of Heart Failure	65
Predictors of Incident Heart Failure Diagnosis Setting	64
Exercise Blood Pressure in Heart Failure With Preserved and Reduced Ejection Fraction	61
Revisiting ICD Therapy for Primary Prevention	61
Recognizing the Top Reviewers and Top Authors of JACC: Heart Failure	60
Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia	56
Racial and Genetic Differences in Presentation of Transthyretin Amyloid Cardiomyopathy With Impaired Left Ventricular Function	55
Acute Decompensated Heart Failure in the Setting of Acute Coronary Syndrome	54

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype	53
Opportunities for Change in Home Health Care in Heart Failure	53
Eating to Prevent Both Heart and Planetary Failure	52
Wearable Remote Patient Monitoring Devices	51
Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status	51
Early U.S. Heart Transplant Experience With Normothermic Regional Perfusion Following Donation After Circulatory Death	51
Associations Between Urinary Metal Levels and Incident Heart Failure	50
Challenges Addressing Prognosis in Advanced Heart Failure	48
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies	48
The Impact of Social Determinants of Health on Timely Detection in Transthyretin Cardiac Amyloidosis	47
Clinical Utility of the H2FPEF Score in Patients With Early Atrial Fibrillation	47
The Path Toward a More Equitable Transplant System	45
Advanced Heart Failure in the Cardiac Intensive Care Unit	44
Peripheral Venous Pressure Measured With a Novel Miniature Transducer in Heart Failure Patients	42
Racial and Genetic Differences	42
Compensation Models in Heart Failure	41
NT-proBNP	40
Cardiopulmonary Exercise Testing With Exercise Echocardiography to Assess Treatment Response in Transthyretin Amyloid Cardiomyopathy	39
GDF-15 in Cardiovascular Disease	39
Inhibiting Both Neprilysin and Phosphodiesterase Type 9	38
Obesity and Heart Failure in Patients With a Reduced Ejection Fraction	38
Prognosis for Acute Myocarditis	38
Are We Waiting Too Long to Implant Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Reduced Left Ventricular Function?	37
Challenges in Cardiomyopathy Gene Therapy Clinical Trial Design	37
From Dispensing Pills to Building Pillars	36
Reply	36
Heart Failure With Preserved Ejection Fraction	36
Impact of SGLT2 Inhibitors on Serum Sodium in Heart Failure With Reduced Ejection Fraction	35
Thank You for the Privilege	34
Absence of Atrial Fibrillation Reduction in REDUCE LAP-HF II	34
Heart Failure in Women	34
A Woman's Work Is Never Done	33
Hyperkalemia-Related Heart Failure Therapy Discontinuation and the Association With Outcomes in Patients With Heart Failure	33
Increasing the Utilization of Sac/Val in Elderly HFrEF Patients Eligible for ARNI Treatment	33
STRONG-HF	33
Influence of Impaired Conduction on Exercise Hemodynamics in Patients With Preserved Ejection Fraction	33
Reply	33
Eplerenone for Nonobstructive Hypertrophic Cardiomyopathy	32
Closing the Gap, A Commentary on Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute Heart Failure	32
High NT-proBNP in Heart Failure	32
Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure	31
Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events	31
Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status	30
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical Sensors	30
Practical Guidance for Hemodynamic Assessment by Right Heart Catheterization in Management of Heart Failure	30
Endothelin Receptor Antagonists and Risk of Heart Failure in CKD	30
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction	29
Treatment Differences in Medical Therapy for Heart Failure With Reduced Ejection Fraction Between Sociodemographic Groups	29
Body Composition and Survival in Patients With Heart Failure	29
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection Fraction	28

Full Issue PDF	28
Every Journey Needs a Guide	27
Value of Invasive Hemodynamic Assessments in Patients Supported by Continuous-Flow Left Ventricular Assist Devices	27
Reevaluating Growth Hormone Therapy in HFrEF	27
Hospital at Home as a Novel Care Strategy for Worsening Heart Failure	27
Facts and Fallacies of Body Composition Analysis in Heart Failure	26
Guideline Recommendations for Sudden Cardiac Death Prevention in Patients With Hypertrophic Cardiomyopathy	26
SGLT2 Inhibitors and Serious Renal Events Among Patients With Heart Failure With Reduced Ejection Fraction	25
Reply	25
Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin	25
Therapeutic Options in Ambulatory Advanced Heart Failure	25
Left Ventricular Dimensions and Clinical Outcomes With a Fully Magnetically Levitated Left Ventricular Assist Device	24
Risk Factors and Temporal Trends of Maternal Heart Failure	24
Natriuretic Peptides and Stratification for ICD Therapy in Nonischemic Heart Failure	24
Winning the Battle of Timely Guideline-Directed Medical Therapy Titration	24
Upper Body Hypoxemia During ECMELLA	24
Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction	24
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure	24
SGLT2 Inhibitors in Patients With Cancer Therapy-Related Cardiotoxicity	23
Obesity and Weight Loss Strategies for Patients With Heart Failure	23
Pregnancy-Induced Hypertensive Disorder and Risks of Future Ischemic and Nonischemic Heart Failure	23
Understanding and Investigating Sex-Based Differences in Heart Transplantation	23
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure	22
Diabetes Therapy With SGLT2i After Heart Transplant	22
Temporal Characteristics of Device-Based Individual and Integrated Risk Metrics in Patients With Chronic Heart Failure	22
Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure	22
Smoking Cessation Reduces the Risk of Heart Failure	22
Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry	22
Chloride in Heart Failure	22
Real-World Experience and 36-Week Outcomes of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten	22
Sacubitril/Valsartan Adherence and Postdischarge Outcomes Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction	22
Management of Heart Failure–Related Cardiogenic Shock	22
National Trends and Disparities in Heart Failure Hospitalizations and Inpatient Outcomes Between 2010-2022	22
Tafamidis in Octogenarians	21
Editorial Board	21
From Better Models to Better Care	21
Use of Cardiopulmonary Stress Testing for Patients With Unexplained Dyspnea Post–Coronavirus Disease	21
Full issue PDF	20
Safety of Right and Left Ventricular Endomyocardial Biopsy in Heart Transplantation and Cardiomyopathy Patients	20
Illuminating a Hidden Risk	20
Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes	20
Moving From Prompts to Praxis With Remote Monitoring	20
Treatment of Obesity in Heart Failure	20
Beyond Coronary Atherosclerosis	19
Plasma Amyloid-β in Relation to Cardiac Function and Risk of Heart Failure in General Population	19
Redefining Pre–Heart Failure With Cardiac Biomarkers	19
Identifying Predictors for Heart Failure Outcomes in Phospholamban p.(Arg14del)–Positive Individuals	19
Expanded Definition of Worsening Heart Failure	19
Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Tafamidis in Cardiac Amyloidosis	19
Critical Importance of Genetic Screening in Family Members	19
Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute Heart Failure	19
Toward a Streamlined Optimization Protocol for Patients With Heart Failure With Reduced Ejection Fraction	19
Instructions for Authors	19
To Infinity and Beyond	18
Full issue PDF	18
Effective and Cost-Conscious Utilization of SGLT2 Inhibitors	18
Any Cardiac Influence of the Structural and Functional Brain Changes in Patients With Takotsubo Syndrome?	18
Walking the Line Between Failure and Remission	18
Isolating Noise From Signals in the Air	18
Setting the Diagnosis of Heart Failure	18
To ‘Plant or Not to ‘Plant, That Is the Question	18
Jump Starting the Heart	17
The p.Asn271Ile Variant in the TNNT2 Gene Is Associated With Low-Risk Late-Onset Hypertrophic Cardiomyopathy	17
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes	17
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure	17
The Jury Is Still Out on A-Type Natriuretic Peptide Deficiency Relative to B-Type Natriuretic Peptides	17
Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction	17
Bounded Rationality and Clinical Guidance Documents for Heart Failure	17
Contemporary Epidemiology, Management, and In-Hospital Outcomes of Acute Myocarditis	17
Unreliable HFpEF Diagnosis by H2FPEF in AF	17
Bereavement and Mortality in Heart Failure	16
Reply	16
Patterns of Left Ventricular Regional Wall Motion Abnormalities After Brain Death and Their Clinical Significance	16
Istaroxime in HFpEF	16
A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of HFrEF	16
Perirenal Adipose Tissue Is Associated With Renal Dysfunction and Abnormal Hemodynamics in Patients With HFpEF	16
Pressure From Within and Without in Heart Failure With Preserved Ejection Fraction	16
Applicability of Vericiguat to Patients Hospitalized for Heart Failure in the United States	16
Refining Endpoint Measures in Clinical Trials for Hypertrophic Cardiomyopathy	16
Physical Activity Trajectories Preceding Incident Heart Failure	16

Full Issue PDF	16
Diet and Heart Failure	15
The Link Between Heart Failure and Neurodegeneration	15
Pulmonary Artery Denervation for Combined Pre– and Post–Capillary Pulmonary Hypertension	15
HFpEF Scores	15
Deactivation of Left Ventricular Assist Devices at the End of Life	15
Cardiac Magnetic Resonance in the Evaluation and Management of Nonischemic Cardiomyopathies	15
Disease Penetrance in Genotype-Positive But Clinically Unaffected Relatives From Families With Dilated Cardiomyopathy	15
Gamified Behavioral Science Intervention to Enhance Trial Enrollment	15
Gender and Race Differences in HeartMate3 Left Ventricular Assist Device as a Bridge to Transplantation	15
Global Heart Failure Trends in Young Adults	15
Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support	15
All That Glitters Is Not Gold	15
Automated Identification of Heart Failure With Reduced Ejection Fraction Using Deep Learning-Based Natural Language Processing	15
Impact of Female Sex on Cardiogenic Shock Outcomes	15
Correction	15
Hemodynamic-Guided Heart Failure Management in Patients With Either Prior HF Hospitalization or Elevated Natriuretic Peptides	15
Articulating the JACC Journals’ Direction in Times of Global Change	15
Rationale and Design of the Dapagliflozin Effect on Cardiovascular Events in Acute Heart Failure (DAPA ACT HF)-TIMI 68 Trial	15
Streamlined Heart Failure Optimization Protocol for Patients With Reduced Left Ventricular Ejection Fraction	15
Navigating Advanced Heart Failure in the Shadow of Primary Graft Dysfunction	15
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction	15
Targeting Inflammation in Heart Failure Prevention	14
Impact of Coronary Artery Disease in Women With Newly Diagnosed Heart Failure and Reduced Ejection Fraction	14
Reply	14
Low Serum Ferritin Might Predict Incident Heart Failure	14
Prevalence and Incidence of Pre-HF Among Hispanics/Latinos	14
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction	14
Exertional Dyspnea Can Now Be Graded Using Normative Reference Equations	14
Shedding Light on the Darkness of MYH7 Cardiomyopathies	14
Depressive Symptoms and Incident Heart Failure Risk in the Southern Community Cohort Study	14
Reply	14
Correction	14
Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure	13
Medication Optimization Clinic	13
The Enigma of Natriuretic Peptides	13
Multifactorial Predisposition in Biopsy-Proven Autoimmune and Viral Myocarditis	13
Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy	13
Patient Preference Should Take Precedence in Status 2 Listing for Heart Transplantation	13
Navigating the Global Burden of Pulmonary Arterial Hypertension	13
Nonsteroidal and Steroidal Mineralocorticoid Antagonists	13
Reducing Pediatric Heart Failure Readmissions	13
The Lure of Cardiac Metabolism in the Diagnosis, Prevention, and Treatment of Heart Failure	12
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction	12
Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure	12
Pre–Heart Failure Longitudinal Change in a Hispanic/Latino Population-Based Study	12
Thin Evidence, Heavy Need	12
Angiotensin-Neprilysin Inhibition and Left Ventricular Assist Device Therapy	12
Aging in Heart Failure	12
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial	12
Heart Failure With Preserved Ejection Fraction in Patients With Atrial Fibrillation	12
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF	12
Contemporary American and European Guidelines for Heart Failure Management	12
Full issue PDF	11
Reflections on Early Rehabilitation in Acute Heart Failure	11
The HeartMate 3 Risk Score	11
Cardiac Magnetic Resonance Imaging vs Coronary Angiography as Primary Strategy in Newly Diagnosed Heart Failure	11
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction	11
Temporal Trends, Risk Factors, and Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation	11
Redefining Boundaries in Heart Failure Care	11
Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients	11
Cost and Value in Contemporary Heart Failure Clinical Guidance Documents	11
Correction	11
m-Health Based Cardiac Rehabilitation Program for Management of Older Patients With HFpEF	11
Pregnancy as a Sentinel Event	11
Information for Authors	11
Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction	11
Better 3 Hours Too Soon Than 1 Minute Late	11
Coronary Artery Disease Is Still a Major Cause of Heart Failure	11
Fibrosis Biomarkers Predict Cardiac Reverse Remodeling	11
Hypertrophic Cardiomyopathy With Midventricular Obstruction Is Not Nonobstructive Hypertrophic Cardiomyopathy	11
Guideline-Recommended Therapy Following Hospitalization for Heart Failure	11
Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy	11
Standardizing Histopathological Evaluation of Resected Myocardium in Obstructive Hypertrophic Cardiomyopathy	11
Can Sensor Implantation Alone Reduce Heart Failure Hospitalizations Without Need for Structured Management Based on its Data?	10
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction	10
Iron Deficiency Definition and Management in Patients With Heart Failure	10
Officers Page	10
When the Data Changes, So Should We	10
Trajectories of Kidney Function in Heart Failure Over a 15-Year Follow-Up	10
Heart Failure and the Risk of Stroke	10
Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction	10
Management of Patients With Impella 5.5 Left Ventricular Assist Devices on a Cardiovascular Stepdown Unit	10
Renal Compression in Heart Failure	10
Barriers and Facilitators to Prescribing Guideline-Directed Medical Therapy for Heart Failure in the Indian Health Service	10
Promoting Representation in Heart Failure Clinical Trials	10
24-Month Outcomes of Endovascular Baroreflex Amplification With the MobiusHD Device in Heart Failure With Reduced Ejection Fraction	10
Frailty Status Modifies the Efficacy of ICD Therapy for Primary Prevention Among Patients With HF	10
Reply	10
REPLY	10
“Pharmacoequity” in Heart Failure Treatment	10
Low Education Levels Linked to Increased Mortality Following Acute Heart Failure Hospitalization in Brazil	10
Sex, Temporary Mechanical Circulatory Support, and Heart Transplantation	10
Ending the Fear Depriving Patients With HFpEF and CKD of Lifesaving Therapies	9
Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation	9